US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% SNDK $1,719.99 ▲+0.00% NVDA $233.95 ▲+0.00% SPCX $158.96 ▲+0.00% AMD $633.91 ▲+0.00% MSTR $160.01 ▲+0.00% ASML $1,867.31 ▲+0.00%
FinancialContent

Articles published by Genmab A/S

< Previous 1 2 3 4 Next >
News headline image
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Announces Financial Results for the Nine Months of 2025
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
From Genmab A/S
Via Business Wire
Tickers GMAB MRUS
News headline image
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
From Genmab A/S
Via GlobeNewswire
News headline image
Major Shareholder Announcement
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC)
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Genmab Announces Financial Results for the First Half of 2025
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Announces Changes to its Executive Committee
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Genmab Announces Financial Results for the First Quarter of 2024
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025
From Genmab A/S
Via GlobeNewswire
News headline image
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
From Genmab A/S
Via GlobeNewswire
News headline image
EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Genmab Publishes 2024 Annual Report
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024
From Genmab A/S
Via GlobeNewswire
News headline image
Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
From Genmab A/S
Via Business Wire
Tickers GMAB
< Previous 1 2 3 4 Next >